Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.

Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, Roberts JA, Adane ED, Yamamoto M, Santos-Buelga D, Martín-Suarez A, Simon N, Taccone FS, Lo YL, Barcia E, Struys MMRF, Eleveld DJ.

Clin Pharmacokinet. 2019 Jun;58(6):767-780. doi: 10.1007/s40262-018-0727-5.

2.

Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.

Elsoueidi R, Lander MJ, Richa EM, Adane ED.

J Oncol Pharm Pract. 2016 Apr;22(2):271-4. doi: 10.1177/1078155215583523. Epub 2015 Apr 22.

PMID:
25908647
3.

Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

Adane ED, Herald M, Koura F.

Pharmacotherapy. 2015 Feb;35(2):127-39. doi: 10.1002/phar.1531. Epub 2015 Feb 3.

PMID:
25644478
4.

Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.

Tsakalozou E, Adane ED, Liang Y, Arnold SM, Leggas M.

Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54. doi: 10.1007/s00280-014-2472-2. Epub 2014 May 8.

PMID:
24807458
5.
6.

Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Adane ED, Liu Z, Xiang TX, Anderson BD, Leggas M.

Pharm Res. 2012 Jul;29(7):1722-36. doi: 10.1007/s11095-011-0617-0. Epub 2011 Nov 9.

PMID:
22068278
7.

Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

Adane ED, Liu Z, Xiang TX, Anderson BD, Leggas M.

Pharm Res. 2010 Jul;27(7):1416-25. doi: 10.1007/s11095-010-0137-3. Epub 2010 Apr 29.

PMID:
20428932

Supplemental Content

Loading ...
Support Center